Which step comes immediately after preclinical testing?

Which step comes immediately after preclinical testing?

• A. Formulation and scale-up
• B. File IND
• C. Human clinical trials
• D. NDA filing

Answer: (A)

The step after preclinical testing is to develop a final formulation and scale up production. Once you’ve shown safety and some efficacy in lab and animal studies, you need a drug product that can be reliably manufactured and delivered to humans in a consistent dose. This involves selecting the dosage form (how the drug is given), optimizing stability, bioavailability, and compatibility, and establishing a scalable manufacturing process under good manufacturing practices. Having a defined formulation and a scalable process provides the essential chemistry, manufacturing, and controls information needed to support regulatory plans and the subsequent submission to authorize clinical studies. With a solid formulation and manufacturing plan in place, the next regulatory move is to file the IND to begin human trials; after successful trials, you’d move on to NDA filing for approval to market. The practical reason the formulation and scale-up step comes first is that you can’t meaningfully proceed with human testing or regulatory submissions without a well-characterized, reproducible drug product.

The step after preclinical testing is to develop a final formulation and scale up production. Once you’ve shown safety and some efficacy in lab and animal studies, you need a drug product that can be reliably manufactured and delivered to humans in a consistent dose. This involves selecting the dosage form (how the drug is given), optimizing stability, bioavailability, and compatibility, and establishing a scalable manufacturing process under good manufacturing practices. Having a defined formulation and a scalable process provides the essential chemistry, manufacturing, and controls information needed to support regulatory plans and the subsequent submission to authorize clinical studies. With a solid formulation and manufacturing plan in place, the next regulatory move is to file the IND to begin human trials; after successful trials, you’d move on to NDA filing for approval to market. The practical reason the formulation and scale-up step comes first is that you can’t meaningfully proceed with human testing or regulatory submissions without a well-characterized, reproducible drug product.